Financial Constraints to Molecular Biomarker Testing

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.

Related Videos

September 20, 2013

Cost, Value and Access of Personalized Medicine

Linda Bosserman provides an overview of the nuances of personalized medicine as it relates to cost, value and access

January 20, 2016

Therapeutic Agents in Clinical Trials

Dr Wainberg and Dr Gerson identify some of the challenges of preclinical models versus clinical trials.